The story of Viagra presents a nuanced case for investors in the medicinal sector. While initially a phenomenal success, generating billions, the patent expiration and the subsequent arrival of off-brand alternatives have significantly impacted income. This poses questions about the long-term sustainability of related medication innovations and … Read More